<DOC>
	<DOCNO>NCT01876927</DOCNO>
	<brief_summary>Study design : Multicenter , randomize , open label phase II study Arm A : DOX 4 cycle - Surgery - Follow-up Arm B : DOX 2 cycle - Surgery - DOX 2 cycle - Follow-up Population : Male female , 18-75 year age , diagnosis histologically confirm , potentially resectable adenocarcinoma stomach . Sample Size : Planned sample size 90 patient , 45 patient arm ( p0=50 % , p1=80 % , alpha=0.05 ( two side ) , beta=0.2 ) Treatment Plan : Treatment administer 4 2 cycle surgery arm A B , respectively , arm B 2 cycle surgery unless progression unacceptable toxicity occur , patient refuse treatment . In case patient go treatment . 3-6 week end fourth ( arm A ) second ( arm B ) preoperative cycle , patient undergo surgery . After surgery 3-6 week surgery patient arm B receive 2 cycle . DOX : Docetaxel 35 mg/m2 day 1 8 Oxaliplatin 80 mg/m2 day 1 Capecitabine 750 mg/m2 x 2 daily 2 week Cycles repeat every 3 week Evaluation criterion : Tumor assessment perform accord RECIST criterion ( version 1.1 ) . Duration Study : Overall study duration : 07/2010- 03/2017 Planned study duration per patient : 5 year</brief_summary>
	<brief_title>Pre-Operative Or Peri-Operative Dox Regimen In Patients With Locally Advanced Resectable Gastric Cancer</brief_title>
	<detailed_description>Title : A randomised phase II study pre-operative peri-operative docetaxel , oxaliplatin , capecitabine ( DOX ) regimen patient locally advance resectable gastric cancer . Clinical Phase : II Study Objectives : Primary : The percentage patient receive plan chemotherapeutic cycle . Secondary : - Downstaging accord Recist criterion - pT1-3 v pT0 . - Safety : number patient grade 3-4 toxicity - The role PET Scan predictor response - Curative v palliative surgery - TTP - OS - Diagnostic correlation various stag method - Possible correlation CT scan , CT/PET , laparoscopy ; - Molecular marker related toxicity : DPYD , MTHFR , TS , XPD , ERCC1 , XRCC1 ; - Molecular marker related prognosis : TYMS , GSTP1 , COX-2 , RUNX3 , methylation profile ( Cox2 , hMLH1 , MGMT ) ; - Molecular marker related therapy response : TYMS , DPYD , MTHFR , OPRT , ERCC1 , XRCC1/2/3 , GSTP1 , GSTM1 , GSTT1 , ABCB1 , methylation profile ( Cox2 , hMLH1 , MGMT ) , whole genome arrayCGH . Study design : Multicenter , randomize , open label phase II study Arm A : DOX 4 cycle - Surgery - Follow-up Arm B : DOX 2 cycle - Surgery - DOX 2 cycle - Follow-up Population : Male female , 18-75 year age , diagnosis histologically confirm , potentially resectable adenocarcinoma stomach . Sample Size : Planned sample size 90 patient , 45 patient arm ( p0=50 % , p1=80 % , alpha=0.05 ( two side ) , beta=0.2 ) Treatment Plan : Treatment administer 4 2 cycle surgery arm A B , respectively , arm B 2 cycle surgery unless progression unacceptable toxicity occur , patient refuse treatment . In case patient go treatment . 3-6 week end fourth ( arm A ) second ( arm B ) preoperative cycle , patient undergo surgery . After surgery 3-6 week surgery patient arm B receive 2 cycle . DOX : Docetaxel 35 mg/m2 day 1 8 Oxaliplatin 80 mg/m2 day 1 Capecitabine 750 mg/m2 x 2 daily 2 week Cycles repeat every 3 week Evaluation criterion : Tumor assessment perform accord RECIST criterion ( version 1.1 ) . Duration Study : Overall study duration : 07/2010- 03/2017 Planned study duration per patient : 5 year</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Signed write informed consent 2 . Male female 1875 year age 3 . Diagnosis histologically confirm , potentially resectable adenocarcinoma stomach 4. cT3 subserosal cT4a cT4b ( 7th edition UICC TNM ) bulky lymph node metastases independently T 5 . ECOG performance status 01 study entry 6 . Laboratory requirement ( ≤ 7 day prior chemotherapy start ) : 1 . Hematology : I ) Neutrophils &gt; 1.5 x 109 /L II ) Platelets &gt; 100 x 109 /L III ) Hemoglobin &gt; 10g/dL 2 . Hepatic function I ) Total bilirubin &lt; 1.25 UNL II ) AST ( SGOT ) ALT ( SGPT ) &lt; 2.5xUNL III ) Alkaline phosphatase &lt; 2.5xUNL 3 . Renal function I ) Creatinine &lt; 1.5 UNL In event borderline value , calculate creatinine clearance &gt; 60 mL/min ; Written inform consent sign date randomization procedure , include expect cooperation patient treatment followup , must obtain document accord local regulatory requirement . Effective contraception male female patient risk conception exist 1 . Early gastric cancer ( N0 ) 2 . T2 ( accord 7th edition UICC TNM ) N0 3 . Linitis plastica 4 . Positive peritoneal cytology 5 . Distant metastases 6 . Neoplasm involve gastroesophageal junction 7 . Pertoneal involvement 8 . Concurrent chronic systemic immune therapy 9 . Any investigational agent ( ) administer 4 week prior entry 10 . Clinically relevant coronary artery disease , history myocardial infarction hypertension control therapy within last 12 month 11 . Known grade 3 4 allergic reaction component treatment 12 . Known drug abuse/alcohol abuse 13 . Legal incapacity limit legal capacity 14 . Medical psychological condition , opinion investigator , would permit patient complete study sign meaningful inform consent 15 . Women pregnant breastfeed 16 . Acute subacute intestinal occlusion 17 . Any concurrent malignancy nonmelanoma skin cancer , carcinoma situ cervix . ( Patients previous malignancy without evidence disease ≥ 5 year allow enter trial )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Locally</keyword>
	<keyword>Advanced</keyword>
	<keyword>Resectable</keyword>
	<keyword>Gastric Cancer</keyword>
</DOC>